Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 8Multiple Myeloma 2Carcinoma, Ovarian Epithelial 2Recurrence 1Peritoneal Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1Advanced Malignancies 1

Interventions

Paclitaxel 16Carboplatin 14Cisplatin 12Oxaliplatin 9Hyperthermic Intraperitoneal Chemotherapy 9Cytoreduction Surgical Procedures 9Fluorouracil 7Bevacizumab 7Doxorubicin 5Leucovorin 4Gemcitabine 4catumaxomab 3Docetaxel 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nintedanib 2liposomal doxorubicin 2epothilone B 2Surgical Procedures, Operative 2Palliative Care 2Mitomycin 2Laparoscopy 2Interviews as Topic 2Drug Therapy 2Blood Specimen Collection 2veliparib 1tremelimumab 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Peritoneal Neoplasms × 1-dodecylpyridoxal × Clear all
NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 21 charts
Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡